{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:58:05Z","timestamp":1790762285910,"version":"4.1.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0199708","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T14:21:55Z","timestamp":1531923715000},"page":"e0199708","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of CD52 expression in \"double-hit\" and \"double-expressor\" lymphomas: Implications for clinical trial eligibility"],"prefix":"10.1371","volume":"13","author":[{"given":"Jeffrey W.","family":"Craig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Crombie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine S.","family":"Pinkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-0344","authenticated-orcid":true,"given":"Olga","family":"Pozdnyakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,7,18]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2016.09.004","article-title":"High grade B-cell lymphoma with rearrangements of MYC and BCL2 and\/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma","volume":"31","author":"A Rosenthal","year":"2017","journal-title":"Blood Rev"},{"issue":"20","key":"ref2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"SH Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"28","key":"ref3","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"NA Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"28","key":"ref4","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"TM Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Y Oki","year":"2014","journal-title":"Br J Haematol"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3324\/haematol.2014.113852","article-title":"A hostel for the hostile: the bone marrow niche in hematologic neoplasms","volume":"100","author":"DS Krause","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.cell.2013.12.041","article-title":"Sensitizing protective tumor microenvironments to antibody-mediated therapy","volume":"156","author":"CP Pallasch","year":"2014","journal-title":"Cell"},{"issue":"22","key":"ref8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood.V128.22.47.47","article-title":"Harnessing the Tumor Microenvironment for the Treatment of Double Hit Lymphoma","volume":"128","author":"C Lossos","year":"2016","journal-title":"Blood"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2006.05.006","article-title":"CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells","volume":"120","author":"T Watanabe","year":"2006","journal-title":"Clin Immunol"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H","volume":"22","author":"L Ginaldi","year":"1998","journal-title":"Leuk Res"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"e39416","DOI":"10.1371\/journal.pone.0039416","article-title":"Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis","volume":"7","author":"SP Rao","year":"2012","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.critrevonc.2015.08.014","article-title":"A review of monoclonal antibody therapies in lymphoma","volume":"97","author":"EC Teo","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref13","unstructured":"LaCasce AS. A Phase 1 Study of Cyclophosphamide and Alemtuzumab in CD52 Positive Relapsed\/Refractory Double-Hit Lymphoma, Diffuse Large B-cell Lymphoma or High Grade B-cell Lymphoma, NOS with MYC and BCL-2 Over-expression, MYC-Positive Transformed Follicular Lymphoma, and CD52 Positive Mature T-cell Lymphoproliferative Disorder. (2017). Retrieved from <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/ct2<\/ext-link> (Identification No. NCT03132584)."},{"issue":"23","key":"ref14","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"SJ Rodig","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref15","first-page":"585","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2017"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"CP Hans","year":"2004","journal-title":"Blood"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience","volume":"34","author":"G Salles","year":"2017","journal-title":"Adv Ther"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/CCO.0000000000000209","article-title":"Primary refractory diffuse large B cell lymphoma in the rituximab era","volume":"27","author":"C Sarkozy","year":"2015","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure-what to do?","volume":"2016","author":"B Coiffier","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"e106745","DOI":"10.1371\/journal.pone.0106745","article-title":"Rate of primary refractory disease in B and T-cell non-Hodgkin&apos;s lymphoma: correlation with long-term survival","volume":"9","author":"C Tarella","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d&apos;Etudes des Lymphomes de l&apos;Adulte","volume":"116","author":"B Coiffier","year":"2010","journal-title":"Blood"},{"issue":"20","key":"ref22","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2012-01-406033","article-title":"MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation","volume":"119","author":"W Cuccuini","year":"2012","journal-title":"Blood"},{"issue":"20","key":"ref23","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"J Hiraga","year":"2009","journal-title":"Blood"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-2141.2002.03843.x","article-title":"Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin&apos;s lymphoma: a retrospective review","volume":"119","author":"GA Kennedy","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.seminoncol.2014.08.006","article-title":"Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance","volume":"41","author":"B Bonavida","year":"2014","journal-title":"Semin Oncol"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.blre.2016.08.001","article-title":"Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab","volume":"31","author":"M Ku","year":"2017","journal-title":"Blood Rev"},{"issue":"14","key":"ref27","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"M Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3109\/10428194.2014.982636","article-title":"Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era","volume":"56","author":"CS Lu","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4143\/crt.2013.45.2.112","article-title":"Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement","volume":"45","author":"BW Kang","year":"2013","journal-title":"Cancer Res Treat"},{"key":"ref30","article-title":"Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy","author":"Z Yao","year":"2017","journal-title":"Leukemia"},{"issue":"15","key":"ref31","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S1470-2045(15)00005-4","article-title":"Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas","volume":"16","author":"C Sarkozy","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"K Weiskopf","year":"2015","journal-title":"MAbs"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1084\/jem.20150295","article-title":"The interaction of anticancer therapies with tumor-associated macrophages","volume":"212","author":"A Mantovani","year":"2015","journal-title":"J Exp Med"},{"issue":"8","key":"ref34","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/onc.2012.117","article-title":"Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies","volume":"32","author":"I Leskov","year":"2013","journal-title":"Oncogene"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1309\/BA3U-RMTU-D7UJ-M8DR","article-title":"Immunophenotyping large B-cell lymphomas. Flow cytometric pitfalls and pathologic correlation","volume":"116","author":"HC Bertram","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"ref36","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"DW Scott","year":"2014","journal-title":"Blood"},{"issue":"6","key":"ref37","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1309\/8UVF7YQ1D4D4ETQV","article-title":"Instability of immunophenotype in plasma cell myeloma","volume":"129","author":"W Cao","year":"2008","journal-title":"Am J Clin Pathol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0199708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T19:55:15Z","timestamp":1571601315000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0199708"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,7,18]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0199708","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,18]]}}}